Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
This Summary of Research summarises results from the BE OPTIMAL (NCT03895203) and BE COMPLETE (NCT03896581) studies and their open-label extension, BE VITAL (NCT04009499). These phase 3 studies looked at how well bimekizumab treatment worked in patients with psoriatic arthritis, and the safety of bimekizumab treatment, over the long term. Two patient groups were included in these studies: patients who had not previously been treated with biologic disease-modifying antirheumatic drugs (bDMARD-naïve; BE OPTIMAL) and patients who had a poor response or were intolerant to tumour necrosis factor (TNF) inhibitors (BE COMPLETE). These studies showed that the beneficial effects of bimekizumab treatment on patients' symptoms reported at year 1 of treatment were sustained up to 2 years, regardless of whether patients were bDMARD-naïve or had previously had a poor response or intolerance to TNF inhibitors. Bimekizumab was well tolerated up to 2 years. The data from this study may help clinicians and patients when they are making shared decisions on treatment options for psoriatic arthritis.
Authors
- Robert Landewé (ORCID: https://orcid.org/0000-0002-0577-6620)
- Barbara Ink
- Akihiko Asahina (ORCID: https://orcid.org/0000-0001-6127-3182)
- Yoshiya Tanaka (ORCID: https://orcid.org/0000-0002-0807-7139)
- Christopher T. Ritchlin (ORCID: https://orcid.org/0000-0002-2602-1219)
- Jason Coarse
- Rajan Bajracharya (ORCID: https://orcid.org/0009-0000-7857-8783)
- Joseph Frank Merola (ORCID: https://orcid.org/0000-0001-6514-4353)
- Iain B. McInnes (ORCID: https://orcid.org/0000-0002-6462-4280)
- Philip J. Mease (ORCID: https://orcid.org/0000-0002-6620-0457)
- Laura C. Coates (ORCID: https://orcid.org/0000-0002-4756-663X)
- Laure Gossec (ORCID: https://orcid.org/0000-0002-4528-310X)
- Andrea Heinrichs
- Vishvesh Shende
Institutions
- Jikei University School of Medicine (JP)
- Inserm (FR)
- University of Occupational and Environmental Health Japan (JP)
- Sorbonne Université (FR)
- University of Oxford (GB)
- Swedish Medical Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Pitié-Salpêtrière Hospital (FR)
- Zuyderland Medisch Centrum (NL)
- Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR)
- Oxford University Hospitals NHS Trust (GB)
- UCB Pharma (Germany) (DE)
- Southwestern Medical Center (US)
- University of Rochester (US)
- University of Glasgow (GB)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Rheumatology and Therapy
- Published
- 2025-05-10
- DOI
- https://doi.org/10.1007/s40744-025-00764-8
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- UCB Pharma